company background image
BU

Burcon NutraScience TSX:BU Stock Report

Last Price

CA$0.50

Market Cap

CA$54.4m

7D

-18.0%

1Y

-86.5%

Updated

28 Jun, 2022

Data

Company Financials +
BU fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BU Stock Overview

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada.

Burcon NutraScience Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Burcon NutraScience
Historical stock prices
Current Share PriceCA$0.50
52 Week HighCA$3.85
52 Week LowCA$0.50
Beta2
1 Month Change-43.18%
3 Month Change-57.63%
1 Year Change-86.49%
3 Year Change-28.57%
5 Year Change-63.77%
Change since IPO-37.50%

Recent News & Updates

May 19
Burcon NutraScience (TSE:BU) Is In A Good Position To Deliver On Growth Plans

Burcon NutraScience (TSE:BU) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

BUCA ChemicalsCA Market
7D-18.0%-2.0%-0.4%
1Y-86.5%38.7%-2.9%

Return vs Industry: BU underperformed the Canadian Chemicals industry which returned 38.1% over the past year.

Return vs Market: BU underperformed the Canadian Market which returned -2.6% over the past year.

Price Volatility

Is BU's price volatile compared to industry and market?
BU volatility
BU Average Weekly Movement10.3%
Chemicals Industry Average Movement12.9%
Market Average Movement10.1%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: BU is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: BU's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199825Peter Kappelhttps://www.burcon.ca

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. Its products include Peazazz, a pea protein for dairy alternative products, such as protein bars and crisps, weight management and meal replacement products, and vegetarian and vegan foods, as well as dry blended and ready-to-drink beverages; and Peazac, a pea protein for plant-based meat alternative products, ready-to-mix powders and beverages, dairy alternatives, nutrition bars, and other applications. The company also provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods.

Burcon NutraScience Fundamentals Summary

How do Burcon NutraScience's earnings and revenue compare to its market cap?
BU fundamental statistics
Market CapCA$54.36m
Earnings (TTM)-CA$10.26m
Revenue (TTM)CA$171.47k

318.5x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BU income statement (TTM)
RevenueCA$171.47k
Cost of RevenueCA$1.45m
Gross Profit-CA$1.28m
Other ExpensesCA$8.98m
Earnings-CA$10.26m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.094
Gross Margin-744.37%
Net Profit Margin-5,982.59%
Debt/Equity Ratio0%

How did BU perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BU?

Other financial metrics that can be useful for relative valuation.

BU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue276.6x
Enterprise Value/EBITDA-7.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does BU's PB Ratio compare to its peers?

BU PB Ratio vs Peers
The above table shows the PB ratio for BU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.2x
CZO Ceapro
1.6xn/aCA$46.7m
VNP 5N Plus
0.7x154.4%CA$126.3m
GGG G6 Materials
1.4xn/aCA$11.5m
NANO Nano One Materials
5x-10.3%CA$251.5m
BU Burcon NutraScience
1.9x66.0%CA$54.4m

Price-To-Book vs Peers: BU is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (2.2x).


Price to Earnings Ratio vs Industry

How does BU's PE Ratio compare vs other companies in the CA Chemicals Industry?

Price-To-Book vs Industry: BU is good value based on its Price-To-Book Ratio (1.9x) compared to the Canadian Chemicals industry average (2.2x)


Price to Book Ratio vs Fair Ratio

What is BU's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BU PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BU's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BU (CA$0.5) is trading below our estimate of fair value (CA$1.39)

Significantly Below Fair Value: BU is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BU's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Burcon NutraScience forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


66.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BU's revenue (43.3% per year) is forecast to grow faster than the Canadian market (7% per year).

High Growth Revenue: BU's revenue (43.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BU's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Burcon NutraScience performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BU is currently unprofitable.

Growing Profit Margin: BU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BU is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare BU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BU is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (30.2%).


Return on Equity

High ROE: BU has a negative Return on Equity (-36.32%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Burcon NutraScience's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BU's short term assets (CA$7.6M) exceed its short term liabilities (CA$1.0M).

Long Term Liabilities: BU's short term assets (CA$7.6M) exceed its long term liabilities (CA$58.7K).


Debt to Equity History and Analysis

Debt Level: BU is debt free.

Reducing Debt: BU has no debt compared to 5 years ago when its debt to equity ratio was 44.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BU has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 3.1% each year.


Discover healthy companies

Dividend

What is Burcon NutraScience current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BU's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BU has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

12.8yrs

Average management tenure


CEO

Peter Kappel

0.25

Tenure

CA$298,755

Compensation

Mr. Peter H. Kappel had been Independent Director of Burcon Nutrascience Corporation since January 28, 2016 and serves as its Chairman since September 2021 and also serves as its Interim Chief executive Of...


Leadership Team

Experienced Management: BU's management team is seasoned and experienced (12.8 years average tenure).


Board Members

Experienced Board: BU's board of directors are considered experienced (8.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Burcon NutraScience Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Burcon NutraScience Corporation
  • Ticker: BU
  • Exchange: TSX
  • Founded: 1998
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: CA$54.364m
  • Shares outstanding: 108.73m
  • Website: https://www.burcon.ca

Number of Employees


Location

  • Burcon NutraScience Corporation
  • 1946 West Broadway
  • Vancouver
  • British Columbia
  • V6J 1Z2
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.